



**\$200 Million**  
Follow-On Offering

**svb** Securities  
Joint Bookrunner  
February 2023

## SVB Securities Serves as Joint Bookrunner for Traverse Therapeutics' (Nasdaq: TVTX) \$200 Million Follow-On Offering

### Key Transaction Highlights

- Publicly launched February 27th post-close after limited confidential marketing and priced February 28th post-close
- The offering followed Traverse's February 17th announcement of the FDA's accelerated approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgA Nephropathy (IgAN) at risk of rapid disease progression.
- Well oversubscribed from new and existing investors
- Transaction consisted of 8,275,000 shares of common stock at a price of \$21.00 per share, representing a 3.4% discount to launch and a 5.8% discount to last sale, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,250,000 shares of common stock at a price of \$20.9999 per pre-funded warrant.
- Traverse intends to use the net proceeds from this offering to support the ongoing commercial launch of FILSPARI (sparsentan) for IgAN and, if approved, the commercial launch of sparsentan for FSGS, as well as for general corporate purposes, which may include clinical trial, manufacturing and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
- This is SVB Securities' 4th bookrun offering for Traverse and 8th bookrun equity offering in 2023. SVB Securities previously served as a bookrunner in Traverse's March 2022 convertible senior notes offering as well as the Company's February 2021 and March 2015 follow-on offerings.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON  
53 State Street  
40th Floor  
Boston, MA 02109

CHARLOTTE  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

NASHVILLE  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

NEW YORK  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

SAN FRANCISCO  
255 California Street  
12th Floor  
San Francisco, CA 94111

An SVB Company  
[svbsecurities.com](http://svbsecurities.com)